Abstract
Dengue viruses are the most common arthropod-transmitted viral infection, with an estimated 390 million human infections annually and ~ 3.6 billion people at risk. Currently, there are no approved vaccines or therapeutics available to control the global dengue virus disease burden. In this study, we demonstrate the binding, neutralizing activity, and therapeutic capacity of a novel bispecific dual-affinity retargeting molecule (DART) that limits infection of all four serotypes of dengue virus.
| Original language | English |
|---|---|
| Pages (from-to) | 7747-7753 |
| Number of pages | 7 |
| Journal | Journal of Virology |
| Volume | 87 |
| Issue number | 13 |
| DOIs | |
| State | Published - Jul 2013 |
Funding
| Funders | Funder number |
|---|---|
| National Institute of Allergy and Infectious Diseases | U54AI065359 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Microbiology
- Immunology
- Insect Science
- Virology
Fingerprint
Dive into the research topics of 'Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver